HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era

Table 1

Clinical characteristics and initial treatment of 14 patients with HIV-associated Burkitt lymphoma.

Characteristic	n
Age at BL presentation (years)
≤45	7
>45	7
Age in years, median (range)
45.5 (32–56)
Gender
Male	14
BL stage
I	2
II	1
III	4
IV	7
Magrath risk^1
Low	3
High	11
BCCA risk^2
Low	0
High	14
LDH
Normal	6
Increased	8
ECOG PS^3
0-1	4
≥2	5
Extranodal sites
≥1	7
HIV risk^4
Sexual	9
IDU	3
CD4 at BL diagnosis
<200	4
≥200	10
Prior AIDS^5
No	13
Yes	1
Coinfections
Hepatitis B
Known negative	9
Known positive	3
Hepatitis C
Known negative	10
Known positive	3
HAART^6
No	1
Yes	13
G-CSF
Yes	13
Number of cycles of HD-CT
1-2	4
3-4	10
Received rituximab
No	4
Yes	10

¹Magrath risk: low risk has ≤1 extranodal site of BL and LDH ≤350 IU/L; all others are high risk.
²BCCA risk: low risk has Ann Arbor stage I, II, or III; bulk <5 cm; normal LDH level; all others are high risk.
³ECOG Performance Status, 𝑛=5 not recorded.
⁴HIV Risk, 𝑛=2 not recorded.
⁵Kaposi sarcoma, 𝑛=1.
⁶HAART usually includes one nucleoside analog, one protease inhibitor, and either a second nucleoside analog or a nonnucleoside reverse transcription inhibitor (NNRTI).
AIDS: acquired immunodeficiency syndrome; BCCA: British Columbia Cancer Agency; BL: Burkitt lymphoma; ECOG PS: Eastern Cooperative Oncology Group; G-CSF: granulocyte colony stimulating factor; HIV: Human Immunodeficiency virus; HAART: highly active antiretroviral therapy; HD-CT: high dose chemotherapy; IDU: injection drug use; LDH: lactate dehydrogenase; 𝑛: number of patients.